Bills · S 3345
IN COMMITTEE· 119TH CONGRESS
Senate BillS 3345Health
PBM Price Transparency and Accountability Act
INTRO DEC 4· LAST ACTION DEC 4
READING
53MIN
COSPONSORS
27BIPARTISAN
READER REACTIONS0 TOTAL
NO VOTES YET · BE THE FIRST
- Introduced only
LEGISLATIVE PROGRESS
STEP 2 / 8Introduced
In Committee
Reported
Passed Senate
Passed House
Conference
To President
Became Law
WHAT THE BILL DOES
AI-writtenThis bill matters because it tries to bring more fairness and transparency to how prescription drugs are priced and paid for within the Medicaid program. Currently, a practice called "spread pricing" by Pharmacy Benefit Managers (PBMs) can lead to situations where states pay more for drugs than pharmacies actually receive, potentially inflating costs for taxpayers and limiting resources for other Medicaid services.
If this bill becomes law, it could lead to more accurate and equitable payments for pharmacies, which might help smaller or independent pharmacies stay in business and ensure access to medications for Medicaid patients. It could also potentially save taxpayer money by curbing inflated costs. If it doesn't become law, the current opaque pricing practices and concerns about spread pricing in Medicaid would likely continue.
KEY PROVISIONS
4AI-extractedPROVISION 01
The bill requires the Secretary of Health and Human Services to conduct monthly surveys of retail and non-retail pharmacies to determine the actual acquisition costs of covered outpatient drugs for Medicaid programs.
This ensures that drug payments are based on what pharmacies truly pay for medicines, making the system fairer.
PROVISION 02
Pharmacies in a State that receive any payment related to dispensing Medicaid-covered drugs must respond to these monthly drug price surveys.
This makes participation mandatory, aiming for comprehensive and accurate data collection across all types of pharmacies.
PROVISION 03
Information collected from these drug price surveys, including response rates and any price concessions, will be made publicly available.
Public transparency allows for greater oversight and understanding of drug pricing trends and PBM practices.
PROVISION 04
The Secretary shall establish civil money penalties for pharmacies that refuse to respond to surveys, knowingly provide false information, or otherwise fail to comply with the survey requirements, with penalties up to $100,000 per violation.
These penalties enforce compliance, ensuring that accurate and timely drug cost data is provided.
SPONSORSHIP
1 + 27
R· Idaho
YRS IN OFFICE
33
BILLS LED
30
COSPONSOR BREAKDOWNBIPARTISAN · 88%
DEM 12 REP 15 IND 0
ACTION TIMELINE
2 EVENTSDEC 4
Introduced in Senate
DEC 4
Read twice and referred to the Committee on Finance.
BILL INFO
TypeSenate Bill
NumberS 3345
Congress119th
StatusIn Committee
IntroducedDec 4, 2025
Last actionDec 4, 2025
READER REACTIONS
OVERALL SENTIMENT
No reactions yet. Be the first to weigh in.
Discussion
Loading comments...
IN COMMITTEE· 119TH CONGRESS · FINANCE COMMITTEE · INTRODUCED DEC 4, 2025
Senate BillS 3345Health
PBM Price Transparency and Accountability Act
INTRODUCED DEC 4, 2025· LAST ACTION DEC 4, 2025
PASSAGE CHANCES
—%
READING
53 min
COSPONSORS
27
COMPLEXITY
Moderate
